Illumina: Forecast increase and analyst praise drive trading volume
Reading Time: 3 minutes
Strong numbers: Genomics specialist Illumina exceeds first-quarter earnings per share expectations by more than 9% and raises its annual forecast. Analyst support: The upgrade by the brokerage Piper Sandler to a price target of 200 USD induces sustained institutional accumulation. Strong outlook in operations: The structural recovery in the core business with consumables stabilizes operational margins and solidifies long-term market leadership. The US company Illumina is considered the world's dominant player in the field of next-generation...
Read this article now with a free account.
Your benefits:
- Every month, you can read 5 articles from the premium section for free.
- Monthly 2 trial issues of the Trader newspaper for free.
- Create a personal watchlist with an overview of news about your stock.
